|
11 Apr 2019 |
Intas Pharmaceuticals Launches its Trastuzumab Biosimilar, Eleftha® - Further Bringing Down the Treatment Cost by 65%
|
|
10 Apr 2019 |
Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors
|
|
10 Apr 2019 |
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
|
|
09 Apr 2019 |
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
|
|
09 Apr 2019 |
Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform
|
|
06 Apr 2019 |
Acceleron Discontinues Development of Phase 1 Molecule ACE-2494
|
|
05 Apr 2019 |
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
|
|
05 Apr 2019 |
Merrimack Discontinues Development of MM-310
|
|
05 Apr 2019 |
Fresenius Kabi Receives European Commission Approval For Adalimumab Biosimilar IDACIO
|
|
04 Apr 2019 |
Further record year of biologics sales in 2018 due to innovative antibodies
|
|
03 Apr 2019 |
AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166
|
|
03 Apr 2019 |
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
|
|
03 Apr 2019 |
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
|
|
03 Apr 2019 |
Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
|
|
03 Apr 2019 |
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
|
|
03 Apr 2019 |
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
|
|
03 Apr 2019 |
Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research
|
|
02 Apr 2019 |
Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
|
|
02 Apr 2019 |
Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019
|
|
02 Apr 2019 |
Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11
|
|
02 Apr 2019 |
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
|
|
02 Apr 2019 |
Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
|
|
02 Apr 2019 |
Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
|
|
02 Apr 2019 |
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
|
|
02 Apr 2019 |
Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
|
